Brands Browse Interactions Pill ID Categories

Loading…

Drugvu is an independent compilation of publicly-disclosed pharmaceutical regulatory information. It is not affiliated with the FDA, EMA, MHRA, Health Canada, TGA, TİTCK, PMDA, or any pharmaceutical manufacturer or regulatory agency.

This is not medical advice. Always consult a qualified healthcare professional for medical decisions.

About Editorial process Editorial team Data sources Methodology Corrections Contribute Privacy Terms DMCA Contact

Everolimus and Lorlatinib: Moderate Interaction - Drugvu

🏠›Everolimus›Interaction with Lorlatinib

Everolimus + Lorlatinib

Drug interaction

Moderate interaction

A moderate drug-drug interaction between Everolimus and Lorlatinib is recorded in public interaction data. Severity reflects the source classification; it does not describe your individual risk. Do not start, stop, or change either medicine based on this page.

What “moderate” means

A moderate interaction can matter in some people. The combination is sometimes used, but usually with caution - monitoring, timing changes, or dose adjustments.

What to do

Mention this combination to your pharmacist or prescriber. Do not stop either medicine without advice.

Side effects reported for both

Everolimus and Lorlatinib are each reported to cause the effects below. Taking them together can make these more likely or more pronounced - one of the ways a drug interaction matters.

Malignant Neoplasm ProgressionFatigue

Compiled from public adverse-event reports; an overlap, not a confirmed causal mechanism.

The two medicines

Active ingredient

Everolimus

Mammalian Target Of Rapamycin (Mtor) Kinase Inhibitors

Uses, side effects, dosage →· 332 recorded interactions

Active ingredient

Lorlatinib

Anaplastic Lymphoma Kinase (Alk) Inhibitors

Uses, side effects, dosage →· 439 recorded interactions

Source

DDInter 2.0 (CC-BY 4.0, https://ddinter.scbdd.com)

This is not medical advice. Drugvu is an independent aggregator of public records.